Oct 12, 2022
Neurostimulation for Cognitive Decline; Light at the End of the Tunnel?
AFAIK Dispatch #4
Alzheimer’s Families for Action, Innovation and Knowledge
I have previously lamented the lack of progress on treatments for Alzheimer’s Disease, and called for more aggressive support of neuromodulation approaches. In recent months, there appears to be more clinical support for neurostimulation/neuromodulation approaches.
“A small pilot study published Wednesday in the journal Medicines suggests that patients with Alzheimer’s disease (AD) given daily in-home treatment with NeuroEM Therapeutics’ MemorEM head device maintained their level of cognitive functioning over a period of at least 2.5 years. The company said it plans to initiate a pivotal trial of the transcranial electromagnetic treatment (TEMT) later this year.
MemorEM was granted an FDA breakthrough designation in 2020. The company said its device consists of eight electromagnetic emitters embedded in a soft two-layered cap that together provide treatment to the entire brain.”
Cognito Therapeutics announced Monday that use of its wearable GammaSense stimulation device at 40Hz over six months may reduce white matter atrophy, protect axons and possibly prevent myelin and oligodendrocyte damage in patients with Alzheimer’s disease (AD)…Our therapy can potentially improve outcomes for patients with Alzheimer’s and mild cognitive impairment, as well as other neuro-degenerative diseases that involve loss of white matter and myelination,” commented chief scientific officer Mihaly Hajos.
Results demonstrated that long-term gamma sensory stimulation was safe and well tolerated, with treatment integrating well into participants’ daily lives. According to researchers, efficacy outcomes also indicated “beneficial” clinical effects, including maintenance of cognitive and functional abilities compared to those in the placebo arm, as well as improved sleep quality.
University Research
Recent university research on neuromodulation seems promising.
University of Colorado Anschutz Medical Campus
Icahn School of Medicine at Mount Sinai
University of Southern California, Wake Forest
FYI Note on Earlier AFAIK Dispatch
AFAIK #3 was a brief note on LinkedIn — Progress from one of a handful of actual Alzheimer’s Disease treatments coming to market:
